RBC Starts Cepheid (CPHD) at Outperform
More News related to CPHD
- Cepheid to Webcast Upcoming Financial Presentations
- UBS Downgrades Cepheid (CPHD) to Neutral
- BeaconEquity.com Issues Technical Trade Alerts on Market Movers: YHOO, GOOG, DENN, RFMD, TRID, CPHD
- Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
- Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of 'Start Clean' Strategy
RBC Capital initiates coverage on Cepheid (Nasdaq: CPHD) with an Outperform rating.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
Related Categories
New CoverageStocks Mentioned
-0.69Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
